SBP Prophylaxis in Cirrhosis: Indications and Recommendations

Indications for SBP Prophylaxis

Patients who have recovered from one episode of SBP should receive prophylaxis with continuous oral norfloxacin 400 mg/day or ciprofloxacin 500 mg once daily, as recommended by the European Association for the Study of the Liver, to reduce the probability of SBP recurrence and improve survival 1, 2, 3
All patients with prior SBP should be considered for liver transplantation evaluation due to poor long-term survival, according to the American Association for the Study of Liver Diseases 1, 3

Patients with low ascitic fluid protein concentration (<10-15 g/L) and advanced liver failure should receive prophylaxis, as recommended by the European Association for the Study of the Liver, to reduce the risk of SBP development and improve survival 4, 5
Norfloxacin 400 mg daily significantly improves 3-month survival and reduces SBP development in high-risk patients, according to the American Association for the Study of Liver Diseases 4, 5

All cirrhotic patients with gastrointestinal bleeding should receive antibiotic prophylaxis to prevent SBP, as recommended by the European Association for the Study of the Liver 4, 2
For severe liver disease, IV ceftriaxone 1g daily for 7 days is recommended, according to the American Association for the Study of Liver Diseases 4

Norfloxacin 400 mg daily is the most extensively studied agent for SBP prophylaxis, according to the European Association for the Study of the Liver 1, 4
Ciprofloxacin 500 mg daily is an acceptable alternative and commonly used in the UK, as recommended by the British Society of Gastroenterology 1, 3

Long-term quinolone prophylaxis can lead to increased gram-positive bacterial infections, including MRSA, according to the Centers for Disease Control and Prevention 1, 3
Consider local bacterial resistance patterns when selecting prophylactic antibiotics, as recommended by the World Health Organization 2

Every cirrhotic patient with acute gastrointestinal bleeding requires antibiotic prophylaxis, as bacterial infections occur in 25-65% of these patients and significantly increase rebleeding rates and mortality, with norfloxacin 400 mg orally twice daily for 7 days being an alternative for less severe disease, according to the European Association for the Study of the Liver 6
The American Association for the Study of Liver Diseases recommends IV ceftriaxone 1g daily for 7 days for patients with advanced liver disease during acute gastrointestinal hemorrhage, although the citation for this is not provided, norfloxacin 400 mg orally twice daily for 7 days is an alternative for less severe disease, as stated by the Journal of Hepatology 6

Long-term fluoroquinolone use increases risk of gram-positive infections and multidrug-resistant organisms, with the epidemiology shifting toward more gram-positive cocci and quinolone-resistant bacteria, according to the Journal of Hepatology 6

Indefinite daily norfloxacin 400 mg (or ciprofloxacin 500 mg) in cirrhotic patients with ascites who have survived an SBP episode reduces recurrence from ≈ 68 % to ≈ 20 % and should be continued until liver transplantation or death. [@1]
Prior SBP is the strongest indication for long‑term antibiotic prophylaxis. [@1]
Norfloxacin 400 mg orally once daily is the most extensively studied first‑line agent for secondary prophylaxis. [@1][@2]
Ciprofloxacin 500 mg orally once daily is an acceptable alternative, especially in the United Kingdom. [@2]
Trimethoprim‑sulfamethoxazole 800/160 mg daily is a third‑line option, but evidence supporting its efficacy is less robust. [@1]
Prophylaxis must be continued indefinitely (until transplantation or death); no randomized trials support discontinuation at any time point. [@1]
Without prophylaxis, the 1‑year SBP recurrence rate exceeds 70 %, and 1‑year survival after an SBP episode is only 30‑50 %. [@1][@2]
All patients who survive an SBP episode should be evaluated for liver transplantation eligibility. [@2]

Norfloxacin 400 mg daily (or trimethoprim‑sulfamethoxazole) is recommended when ascitic fluid protein < 1.5 g/dL and at least one of the following is present: serum creatinine ≥ 1 mg/dL, blood urea nitrogen > 25 mg/dL, serum sodium < 130 mEq/L, or Child‑Pugh score > 9 with bilirubin > 3 mg/dL. This recommendation carries Class I, Level B evidence. [@1]
In a randomized trial, continuous norfloxacin reduced SBP incidence from 61 % to 7 % and improved 3‑month survival from 62 % to 94 % in this high‑risk population. [@1]

Every cirrhotic patient with acute gastrointestinal bleeding requires short‑term antibiotic prophylaxis. Class I, Level A evidence. [@1][@3]
For patients with advanced liver disease (Child‑Pugh C, bilirubin > 3 mg/dL), intravenous ceftriaxone 1 g daily for 7 days is the preferred regimen. [@1]
For patients with less severe disease, norfloxacin 400 mg orally twice daily for 7 days is an acceptable alternative. [@1]
A meta‑analysis of 534 patients showed that prophylaxis in the setting of GI bleeding reduced infections by 32 % and increased survival by 9 %. [@4][@1]

Long‑term quinolone prophylaxis selects for resistant organisms, notably gram‑positive bacteria including MRSA. Class II, Level C evidence (as reported). [@2]
One center observed a shift in infection pattern from 67 % gram‑negative to 79 % gram‑positive organisms among patients receiving long‑term quinolone prophylaxis. [@2]
When SBP occurs despite quinolone prophylaxis, empiric therapy should use a third‑generation cephalosporin (e.g., cefotaxime or ceftriaxone) rather than a quinolone, because quinolone‑resistant isolates generally remain susceptible to cefotaxime. [@1]